Construct validity of the PROMIS PF-10 in patients with inflammatory rheumatic diseases and severe limitations in physical functioning-Reference-Cited by-同舟云学术

Construct validity of the PROMIS PF-10 in patients with inflammatory rheumatic diseases and severe limitations in physical functioning

Published:2023-03-20 Issue:6 Volume:52 Page:645-653
ISSN:0300-9742
Container-title:Scandinavian Journal of Rheumatology
language:en
Short-container-title:Scandinavian Journal of Rheumatology

Author:

van Wissen MAT¹^ORCID,Straathof B¹^ORCID,Vliet Vlieland TPM¹^ORCID,van den Ende CHM²³^ORCID,Teuwen MMH¹^ORCID,Peter WF¹^ORCID,den Broeder AA³⁴^ORCID,van den Hout WB⁵^ORCID,van Schaardenburg D⁶^ORCID,van Tubergen AM⁷⁸^ORCID,Gademan MGJ¹⁹^ORCID,van Weely SFE¹^ORCID

Affiliation:

1. Department of Orthopaedics, Rehabilitation and Physical Therapy, Leiden University Medical Center, Leiden, The Netherlands

2. Department of Research, Sint Maartenskliniek, Nijmegen, The Netherlands

3. Department of Rheumatology, Radboud University Medical Center, Nijmegen, The Netherlands

4. Department of Rheumatology, Sint Maartenskliniek, Nijmegen, The Netherlands

5. Department of Biomedical Data Sciences, Leiden University Medical Center, Leiden, The Netherlands

6. Department of Rheumatology, Reade, Center for Rehabilitation and Rheumatology, Amsterdam, The Netherlands

7. Department of Rheumatology, Maastricht University Medical Center, Maastricht, The Netherlands

8. The Netherlands and Care and Public Health Research Institute (CAPHRI), Maastricht University, Maastricht, The Netherlands

9. Department of Clinical Epidemiology, Leiden University Medical Center, Leiden, The Netherlands

Funder

Netherlands Organisation for Health Research and Development

ReumaNederland

Publisher

Informa UK Limited

Subject

Immunology,General Medicine,Immunology and Allergy,Rheumatology

Link

https://www.tandfonline.com/doi/pdf/10.1080/03009742.2023.2182449

Reference39 articles.

1. The ASAS-OMERACT core domain set for axial spondyloarthritis

2. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update

3. 2016 update of the ASAS-EULAR management recommendations for axial spondyloarthritis

4. Two-, six-, and 12-minute walking tests in respiratory disease.

5. Measurement of patient outcome in arthritis